A1M Pharma AB has been listed on Nasdaq First North since 20 June 2017 and is traded under the short name A1M (ISIN code: SE0009973357). Prior to this, the company had been listed on AktieTorget since 3 April 2013.

The share capital amounts to SEK 6,451,284, divided into 8,064,105 shares of only one series. All the shares have a quotient value of SEK 0.80 and entitle the holder to one vote and equal rights to a share in the company’s assets and profits.

Company description 
A1M Pharma’s company description in connection with the listing on Nasdaq First North Stockholm – June 2017. To read the company description, click here.

First North
First North is an alternative marketplace that is managed by the various stock exchanges that make up NASDAQ OMX. It does not have the same legal status as a regulated market. Companies traded on First North are regulated by First North’s rules and not by the legal requirements stipulated for trading on a regulated market. An investment in a company that is traded on First North involves more risk than an investment in a quoted company. All companies whose shares are traded on First North have a Certified Adviser, who monitors the company’s compliance with First North’s rules and regulations for disclosure of information to the market and investors. The Certified Adviser scrutinises companies whose shares are to be admitted for trading on First North.

Dividends

All shares carry equal rights to dividends. Any dividend is declared and approved at the Annual General Meeting (AGM) and paid out after the AGM. Payment of any dividend is administered by Euroclear Sweden AB. Deductions for preliminary tax are normally administered by Euroclear or, for nominee-held shares, by the nominee. Rights to any allocation fall to the person who, on the appointed record day, is entitled to participate in the AGM, i.e. was registered as a shareholder in the share register kept by Euroclear. Shareholders are entitled to a share of the surplus in the event of any liquidation in proportion to the number of shares that the shareholder owns. If a shareholder cannot be reached by Euroclear, the shareholder’s claim against the company for the dividend amount remains and is only limited by rules on limitation. In the event of limitation, the dividend amount passes to the company.

There are no restrictions on dividends or special procedures for shareholders resident outside of Sweden and payment is made by Euroclear in the same manner as for shareholders resident in Sweden. However, shareholders who are not domiciled in Sweden for tax purposes are subject to normal Swedish withholding tax.

In accordance with the Swedish Companies Act, a shareholder who directly or indirectly holds more than 90% of the share capital in a company is entitled to buy out the remaining shares from the other shareholders in the Company. Correspondingly, a shareholder whose shares may be subject to a buy-out is entitled to compel the majority shareholder to purchase said shares.

The company is subject to the Swedish Industry and Commerce Stock Exchange Committee’s (Näringslivets Börskommitté, NBK) rules on mandatory offers and public offers to the shareholders of companies connected to Nasdaq First North (NBK’s rules concerning public takeover offers for shares in Swedish limited companies with shares traded on certain trading platforms). Under these rules a shareholder is obliged to publicly offer to acquire all shares in a company in the event that the shareholder’s shareholding with voting rights exceeds 30%.


Ownership

The number of shareholders in A1M Pharma totals approximately 4,390, with the largest holdings as of 29 December 2017 shown below.

 

Shareholders

 

Name

Number of shares

Share of capital and votes (%)

Baulos International SA / Baulos Capital1

890 690

10,7 %

Avanza Pension

537 836

6,5 %

Handelsbanken Liv Försäkring AB

222 679

2,7 %

Nordnet Pensionsförsäkring

212 149

2,6 %

Ålandsbanken i ägares ställe

164 241

2,0 %

Bo Åkerström* (founder, board member)

132 826

1,6 %

Lars Thomas Jönsson

115 590

1,4 %

Stefan Hansson* (founder, board member)

103 151

1,2 %

Livförsäkringsbolaget Skandia

63 206

0,8 %

Swedbank försäkning

58 055

0,7 %

Other

5 797 017

69,9 %

Total

8 297 440

100 %

1 Including related party and companies


Shareholders’ agreement, etc.
As far as the company’s board of Directors is aware, there are no shareholders’ agreements between the company’s shareholders that aim to exert joint influence over the company. The company’s board of Directors is also unaware of any agreements or equivalent arrangements that may lead to a change of control over the company.

Insiders
From 3 July 2016 insider transactions are to be reported to Finansinspektionen, Sweden’s financial supervisory authority. You can find FI’s insider register here.

Share price

  • A1M -6.01 %
  • buy 5.95
  • sell 6.10
  • latest 6.10

See also Nasdaq First North

Articles of Association
The articles of association are the rules to which a limited company is subject. You can download A1M Pharma’s articles of association by clicking here.

A1M Pharma AB | Scheelevägen 22 | 223 63 Lund
+46 46 286 50 30 | info@a1m.se
Medlem av Preeclampsia Foundation
Legal disclaimer | © Copyright - A1M